USANA Health (USNA)
NYSE:USNA
Top Page
USANA Health
(NYSE:USNA)
Select Model
Select Model
Rating:53Neutral
Price Target:
$18.00
▼(-20.11% Downside)
Action:ReiteratedDate:03/17/26
USNA scores below average primarily due to weakened cash flow and sharply lower profitability despite a strong, low-leverage balance sheet. Technicals add downside pressure with the stock trading below major moving averages and negative momentum. Guidance and retail expansion plans provide some offset, but elevated inventory, margin mix pressure, and high tax-rate guidance constrain the overall score.
Positive Factors
Balance sheet strength
USANA’s very low leverage and large equity base provide durable financial flexibility. With debt-to-equity near 2.6%, the company can fund retail rollouts, working-capital needs, or technology investments without stressing solvency, cushioning execution risk during a multi-quarter turnaround.
Negative Factors
Weak cash generation
Material FCF erosion and weaker cash conversion reduce financial optionality. With FCF covering only ~38% of net income and a 54% YoY decline, the company has less internal capital to fund inventory builds, retail execution, tech investments, or shareholder returns without increasing external financing or diluting flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
USANA’s very low leverage and large equity base provide durable financial flexibility. With debt-to-equity near 2.6%, the company can fund retail rollouts, working-capital needs, or technology investments without stressing solvency, cushioning execution risk during a multi-quarter turnaround.
Read all positive factors
USANA Health (USNA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$334.26M
Dividend YieldN/A
Average Volume (3M)173.43K
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue Growth5.88%
EPS Growth-68.62%
CountryUS
Employees1,700
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)0.60
Shares Outstanding18,456,936
10 Day Avg. Volume170,208
30 Day Avg. Volume173,431
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)0.68
Price to Sales (P/S)0.39
P/FCF Ratio42.35
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue0.21
Enterprise Value/Gross Profit0.26
Enterprise Value/Ebitda2.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.84
Revenue Forecast (FY)$942.40M
USANA Health Business Overview & Revenue Model
Company Description
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that p...
How the Company Makes Money
USANA primarily makes money by selling health and wellness products—most notably dietary supplements and personal care items—through a direct-selling network. Revenue is generated when products are purchased by end customers and/or by the company’...
USANA Health Earnings Call Summary
Earnings Call Date:Feb 17, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 28, 2026
Earnings Call Sentiment Neutral
The call presents a mixed but constructive outlook: clear positives include retail wins for Hiya and Rise Wellness, a 4% midpoint sales growth outlook for FY2026, experienced leadership returning to CEO, and cost savings from workforce realignment. Offsetting these positives are meaningful risks — notably a 48% inventory build, a very high effective tax rate guidance of 55–60%, core-business sales declines, and FY2026 margin pressure from venture-brand mix with Rise only expected to breakeven. Management conveyed confidence and a concrete strategic plan, but several financial and execution risks remain that balance the positive operational developments.Positive Updates
Fiscal 2026 Net Sales Guidance
Management provided consolidated net sales guidance for fiscal 2026 targeting growth of 4% at the midpoint (guidance range provided). The outlook reflects confidence in strategy execution and growth from venture brands (Rise Wellness and Hiya).
Negative Updates
Core Business Year-Over-Year Declines
Management acknowledged the core USANA nutritional business experienced year-over-year sales declines, and while signs of stabilization were noted, the core business remains under pressure and is a key focus for turnaround efforts.
Read all updates
Q4-2025 Updates
Positive
Negative
Fiscal 2026 Net Sales Guidance
Management provided consolidated net sales guidance for fiscal 2026 targeting growth of 4% at the midpoint (guidance range provided). The outlook reflects confidence in strategy execution and growth from venture brands (Rise Wellness and Hiya).
Read all positive updates
Company Guidance
Management guided consolidated net sales for fiscal 2026 to grow about 4% at the midpoint (the outlook reflects a 52‑week fiscal year, one fewer week than FY25), noted inventories rose $35.0 million (48%) to $107.0 million at fiscal‑25 year‑end (with ~80% of that increase driven by Rise Wellness and Hiya) and said elevated inventory levels are expected through FY26 to support retail expansions (Target in April, Costco and other retailers, plus Canada and U.K. rollouts) and plans to begin in‑house manufacturing for Hiya; Rise Wellness is expected to operate at approximately breakeven in FY26 and, along with Hiya, is a primary driver of the sales outlook; the company expects an effective tax rate of 55–60% for FY26; a recent cost realignment affected roughly 10% of the workforce and yielded about $10M of net SG&A savings (some funds being repurposed to growth initiatives); management also cautioned that incremental technology investments are anticipated but not yet included in the FY26 outlook and that gross margins will be influenced by business mix (e.g., thinner margins at Rise).USANA Health Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
86
Very Positive
Cash Flow
40
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 925.26M | 854.50M | 921.01M | 998.60M | 1.19B |
| Gross Profit | 724.40M | 678.75M | 731.62M | 791.32M | 955.53M |
| EBITDA | 90.56M | 98.86M | 123.11M | 130.22M | 192.89M |
| Net Income | 10.76M | 42.03M | 63.79M | 69.35M | 116.50M |
Balance Sheet | |||||
| Total Assets | 742.91M | 748.19M | 632.76M | 596.55M | 577.74M |
| Cash, Cash Equivalents and Short-Term Investments | 158.38M | 181.77M | 330.42M | 288.42M | 239.83M |
| Total Debt | 14.00M | 39.20M | 13.21M | 13.78M | 17.30M |
| Total Liabilities | 156.64M | 161.86M | 135.56M | 162.08M | 182.62M |
| Stockholders Equity | 533.10M | 532.11M | 497.20M | 434.47M | 395.12M |
Cash Flow | |||||
| Free Cash Flow | 8.53M | 50.92M | 56.15M | 93.50M | 108.46M |
| Operating Cash Flow | 22.35M | 60.99M | 70.64M | 103.90M | 121.23M |
| Investing Cash Flow | -10.13M | -213.09M | -11.97M | -12.37M | -14.19M |
| Financing Cash Flow | -40.60M | 9.55M | -14.24M | -30.09M | -181.41M |
USANA Health Technical Analysis
Neutral
22.53
Price Trends
19.14
Negative
19.68
Negative
23.77
Negative
Market Momentum
-0.28
Negative
51.12
Neutral
85.45
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For USNA, the sentiment is Neutral. The current price of 22.53 is above the 20-day moving average (MA) of 17.42, above the 50-day MA of 19.14, and below the 200-day MA of 23.77, indicating a neutral trend. The MACD of -0.28 indicates Negative momentum. The RSI at 51.12 is Neutral, neither overbought nor oversold. The STOCH value of 85.45 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for USNA.
USANA Health Risk Analysis
USANA Health disclosed 43 risk factors in its most recent earnings report. USANA Health reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
USANA Health Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $1.57B | 5.80 | -36.19% | ― | -0.78% | 265.56% | |
63 Neutral | $360.11M | 26.57 | 17.25% | ― | 12.14% | -17.80% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
62 Neutral | $90.34M | 23.18 | 15.30% | ― | 12.44% | -20.33% | |
61 Neutral | $471.48M | 19.90 | 12.18% | ― | 6.62% | -7.85% | |
56 Neutral | $53.09M | 70.54 | 24.97% | 2.81% | 16.77% | 143.30% | |
53 Neutral | $334.26M | -50.11 | 2.03% | ― | 5.88% | -68.62% |
* Consumer Defensive Sector Average
USNA
USANA Health
18.11
-6.38
-26.05%
HLF
Herbalife
15.23
8.62
130.41%
LWAY
Lifeway Foods
23.77
0.17
0.72%
NATR
Nature's Sunshine Products
26.93
14.82
122.38%
LFVN
LifeVantage
4.15
-9.77
-70.18%
FTLF
FitLife Brands
9.62
-2.45
-20.30%
USANA Health Corporate Events
Business Operations and StrategyFinancial Disclosures
USANA Health Reports Mixed Q4 Results Amid Customer Declines
Negative
Feb 18, 2026
USANA Health Sciences reported that for the fourth quarter ended Jan. 3, 2026, net sales rose 6% year over year to $226 million, but the company swung to a net loss of $1.8 million, or $0.10 per diluted share, as active customers in its core nutri...
Business Operations and StrategyFinancial Disclosures
USANA Health Issues Updated 2025-2026 Sales Outlook
Positive
Jan 12, 2026
On January 12, 2026, USANA Health Sciences announced that it expects fiscal 2025 consolidated net sales of about $925 million, modestly above its prior guidance of roughly $920 million, and issued an initial fiscal 2026 net sales outlook of $925 m...
Business Operations and StrategyExecutive/Board Changes
USANA Health Sciences announces CEO leadership transition
Neutral
Jan 8, 2026
On January 8, 2026, USANA Health Sciences announced a leadership transition in which Jim Brown stepped down as chief executive officer and president after three years in the top role and 19 years with the company, remaining in an advisory position...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.